Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Human telomerase reverse transcriptase promoter-driven oncolytic adenovirus with E1B-19 kDa and E1B-55 kDa gene deletions.

Doloff JC, Waxman DJ, Jounaidi Y.

Hum Gene Ther. 2008 Dec;19(12):1383-400. doi: 10.1089/hum.2008.056.

2.

Dual E1A oncolytic adenovirus: targeting tumor heterogeneity with two independent cancer-specific promoter elements, DF3/MUC1 and hTERT.

Doloff JC, Jounaidi Y, Waxman DJ.

Cancer Gene Ther. 2011 Mar;18(3):153-66. doi: 10.1038/cgt.2010.52. Epub 2010 Sep 24. Erratum in: Cancer Gene Ther. 2011 Mar;18(3):228. Jounaidi, Y [added].

3.

Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.

Wang H, Wei F, Li H, Ji X, Li S, Chen X.

Int J Mol Med. 2013 Feb;31(2):377-85. doi: 10.3892/ijmm.2012.1197. Epub 2012 Nov 29.

PMID:
23229955
4.

Therapeutic efficacy of an hTERT promoter-driven oncolytic adenovirus that expresses apoptin in gastric carcinoma.

Liu L, Wu W, Zhu G, Liu L, Guan G, Li X, Jin N, Chi B.

Int J Mol Med. 2012 Oct;30(4):747-54. doi: 10.3892/ijmm.2012.1077. Epub 2012 Jul 25.

PMID:
22842823
5.

Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.

Irving J, Wang Z, Powell S, O'Sullivan C, Mok M, Murphy B, Cardoza L, Lebkowski JS, Majumdar AS.

Cancer Gene Ther. 2004 Mar;11(3):174-85.

PMID:
14726958
6.

Dissecting the roles of E1A and E1B in adenoviral replication and RCAd-enhanced RDAd transduction efficacy on tumor cells.

Wei F, Wang H, Chen X, Li C, Huang Q.

Cancer Biol Ther. 2014 Oct;15(10):1358-66. doi: 10.4161/cbt.29842. Epub 2014 Jul 14.

7.

A novel oncolytic adenovirus expressing Escherichia coli cytosine deaminase exhibits potent antitumor effect on human solid tumors.

Zhang J, Wei F, Wang H, Li H, Qiu W, Ren P, Chen X, Huang Q.

Cancer Biother Radiopharm. 2010 Aug;25(4):487-95. doi: 10.1089/cbr.2009.0752.

PMID:
20735209
8.

A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer.

Wirth T, Zender L, Schulte B, Mundt B, Plentz R, Rudolph KL, Manns M, Kubicka S, K├╝hnel F.

Cancer Res. 2003 Jun 15;63(12):3181-8.

9.

Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.

Liu TC, Wang Y, Hallden G, Brooks G, Francis J, Lemoine NR, Kirn D.

Gene Ther. 2005 Sep;12(17):1333-46.

PMID:
15920462
10.

Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.

Zhang Q, Chen G, Peng L, Wang X, Yang Y, Liu C, Shi W, Su C, Wu H, Liu X, Wu M, Qian Q.

Clin Cancer Res. 2006 Nov 1;12(21):6523-31.

11.

The oncolytic adenovirus targeting to TERT and RB pathway induced specific and potent anti-tumor efficacy in vitro and in vivo for hepatocellular carcinoma.

Zhang W, Cai R, Luo J, Wang Y, Cui Q, Wei X, Zhang H, Qian C.

Cancer Biol Ther. 2007 Nov;6(11):1726-32. Epub 2007 Aug 1.

PMID:
18281783
12.

Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter.

Fujiwara T, Urata Y, Tanaka N.

Curr Cancer Drug Targets. 2007 Mar;7(2):191-201. Review.

PMID:
17346111
13.

The antitumor efficacy of IL-24 mediated by E1A and E1B triple regulated oncolytic adenovirus.

Xiao LL, Wu YM, Qian J, Tan Y, Xie GL, Zhang KJ, Wang YG, Jia XY, Liu XY.

Cancer Biol Ther. 2010 Aug 1;10(3):242-50. Epub 2010 Aug 10.

PMID:
20574150
14.

E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers.

Wakayama M, Abei M, Kawashima R, Seo E, Fukuda K, Ugai H, Murata T, Tanaka N, Hyodo I, Hamada H, Yokoyama KK.

Clin Cancer Res. 2007 May 15;13(10):3043-50.

15.

Preclinical pharmacology and toxicology study of Ad-hTERT-E1a-Apoptin, a novel dual cancer-specific oncolytic adenovirus.

Qi Y, Guo H, Hu N, He D, Zhang S, Chu Y, Huang Y, Li X, Sun L, Jin N.

Toxicol Appl Pharmacol. 2014 Oct 15;280(2):362-9. doi: 10.1016/j.taap.2014.08.008. Epub 2014 Aug 20.

PMID:
25151223
16.

Markedly enhanced cytolysis by E1B-19kD-deleted oncolytic adenovirus in combination with cisplatin.

Yoon AR, Kim JH, Lee YS, Kim H, Yoo JY, Sohn JH, Park BW, Yun CO.

Hum Gene Ther. 2006 Apr;17(4):379-90.

PMID:
16610926
17.

Deletion analysis of Ad5 E1a transcriptional control region: impact on tumor-selective expression of E1a and E1b.

Hedjran F, Shantanu K, Tony R.

Cancer Gene Ther. 2011 Oct;18(10):717-23. doi: 10.1038/cgt.2011.41. Epub 2011 Aug 5.

PMID:
21818136
18.

Modulation of telomerase promoter tumor selectivity in the context of oncolytic adenoviruses.

Bilsland AE, Merron A, Vassaux G, Keith WN.

Cancer Res. 2007 Feb 1;67(3):1299-307.

19.

HCCS1-armed, quadruple-regulated oncolytic adenovirus specific for liver cancer as a cancer targeting gene-viro-therapy strategy.

Xu HN, Huang WD, Cai Y, Ding M, Gu JF, Wei N, Sun LY, Cao X, Li HG, Zhang KJ, Liu XR, Liu XY.

Mol Cancer. 2011 Nov 1;10:133. doi: 10.1186/1476-4598-10-133.

20.

Complete eradication of hepatomas using an oncolytic adenovirus containing AFP promoter controlling E1A and an E1B deletion to drive IL-24 expression.

Zhang KJ, Zhang J, Wu YM, Qian J, Liu XJ, Yan LC, Zhou XM, Xiao RJ, Wang YG, Cao X, Wei N, Liu XR, Tang B, Jiao XY, Chen K, Liu XY.

Cancer Gene Ther. 2012 Sep;19(9):619-29. doi: 10.1038/cgt.2012.40. Epub 2012 Jul 13.

PMID:
22790965

Supplemental Content

Support Center